Genetic marker may predict need for aggressive ALL treatment in children

09/5/2013 | Oncology Nurse Advisor online

The presence of four or more copies of the gene RUNX1 in an abnormal chromosome 21 among children with acute lymphoblastic leukemia was associated with poor outcomes, according to a study in the Journal of Clinical Oncology. This gene amplification "helps identify patients who need more therapy than they may otherwise get," study author Dr. Stephen Hunger said.

View Full Article in:

Oncology Nurse Advisor online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA